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Patrick J. Lamparello, MD, Ronnie Landis, RN, and Thomas S. Riles, MD, New York, NY
Objectives: Stroke puts a major financial burden on our healthcare system. However, carotid duplex scanning performed
as a screening test for occult carotid artery stenosis (CAS) currently is not reimbursed by Medicare. The goals of this study
were to develop a cost-effective stroke screening program, to determine the prevalence of potential causes of stroke in this
population, and to define a population at high risk in which screening would be most effective.
Methods: In a community-based stroke screening program, patients were eligible if they were older than 60 years and had
a history of either hypertension, heart disease, or cigarette smoking, or a family history of stroke. Screening included
blood pressure determination, an electrocardiographic rhythm strip, and a previously validated modified carotid duplex
ultrasound examination to detect CAS 50% or greater. The relationships between standard demographic risk factors and
screening outcomes were analyzed.
Results: Screening was performed in 610 patients. Unilateral or bilateral CAS was detected in 66 patients (10.8%). The
finding of occult CAS was more prevalent than that of new hypertension (2.6%) or new atrial fibrillation (0.5%). Patients
with known hypertension were significantly more likely to have CAS than were those without hypertension (12.7% vs
7.8%; P  .05). Patients with heart disease were significantly more likely to have CAS than were those without heart
disease (18.2% vs 8%; P < .0001). Patients with both risk factors were significantly more likely to have occult carotid
artery disease than were patients without either risk factor (22.1% vs 8.5%; P < .0001). Multivariate analysis with logistic
regression revealed a history of heart disease as an independent predictor of occult carotid artery disease (odds ratio 95%
confidence interval, 1.4-4.4). Type of heart disease was not a significant factor in predicting occult CAS. Direct cost of the
screening, including community outreach, nurses, technicians, support staff, and miscellaneous expenses, was less than
$75 per patient.
Conclusions: In a screening program for treatable causes of potential stroke, CAS was the most commonly diagnosed
disease. More than one of every five patients with known hypertension and heart disease had occult CAS. Known heart
disease of any type was a significant independent predictor of occult CAS. Screening for treatable causes of potential
stroke can be cost-effective. This information could help to further target populations to screen for occult CAS and to
justify reimbursement for screening carotid duplex scanning examinations. (J Vasc Surg 2004;39:44-51.)
Stroke is the third leading cause of death in the United
States, second only to heart disease and cancer.1 Approxi-
mately 83% of all strokes are ischemic, and 7.6% of these
ischemic strokes result in death within 30 days.1 Perhaps
even more important, stroke is a leading cause of serious,
long-term disability. The estimated direct and indirect costs
of caring for patients after stroke in the United States in
2002 were $49.4 billion.1 Certainly, no one would deny
that stroke is a devastating illness, both from the patient’s
perspective and a national health care cost perspective.
Treatment of stroke, once it has occurred, is generally
unsuccessful.1 Approximately 30% of patients who have a
stroke will require long-term institutionalization, and an
additional 30% will require significant assistance with activ-
ities of daily living. Although early thrombolytic treatment
of ischemic stroke has been reported,2 this intervention is
practically limited to the relatively small number of patients
who can be treated at a major medical center within several
hours of their symptoms. It is clear that the optimal treat-
ment for stroke is primary prevention.
Despite these staggering statistics and extensive re-
search in this area, there is no consensus on how to best
prevent ischemic stroke. Weinberger3 estimates that the
incidence of stroke could possibly be reduced by as much as
50% with improved attention to risk factor modification
and identification of direct predisposing conditions such as
atrial fibrillation and carotid artery stenosis (CAS). How-
ever, Hart et al,4 in a systematic review of 22 published
guidelines for prevention of ischemic stroke, found that
current stroke prevention guidelines do not provide ade-
quate methodologic information to permit assessment of
their quality and clinical applicability. Management recom-
mendations in these reports varies widely, particularly with
regard to the issue of carotid endarterectomy (CEA) to
treat asymptomatic stenosis.4
Two additional important factors that enter this equa-
tion are cost-effectiveness and reimbursement. Widespread
screening of neurologically asymptomatic patients for oc-
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cult carotid artery disease has not been performed, gener-
ally because of the cost. Carotid duplex ultrasound scan-
ning is time-intensive and requires use of a trained vascular
technologist and expensive equipment. Cost analyses have
varied extensively in their assumptions, assessments, and
conclusions regarding screening for and treating asymp-
tomatic carotid artery disease in a variety of patient popu-
lations.5-12 Because widespread screening in the general
population is generally thought to be of low value and not
cost-effective, the cost of examinations performed to screen
for occult CAS currently is not reimbursed by Medicare.
However, as Zwolak13 has stated, “The ultrasound studies
performed to evaluate vascular disease today meet all expec-
tations for safety and accuracy, and cost thousands of
dollars less than their contrast counterparts, yet few sectors
in medicine have been challenged so regularly by the
Health Care Financing Administration.” Several authors
have attempted to develop more rapid and cost-effective
protocols for carotid duplex ultrasound scanning to address
this problem.14,15
With these issues in mind, the objectives of this study
were to develop a cost-effective stroke screening program,
to determine the prevalence of potential causes of stroke in
this population, and to define a population at high risk in
which screening would be most effective.
PATIENTS AND METHODS
Screening protocol. A community-based stroke pre-
vention screening protocol was developed at New York
University Medical Center. The screening was advertised in
flyers and on billboards in the immediate area of our
hospital, and was additionally advertised in several local
community newspapers. Screening was free to subjects.
Subjects were eligible for screening if they were at least 60
years old and had at least one of the following risk factors:
history of cardiac disease, diagnosed hypertension, history
of smoking, and family history of stroke. Subjects could
have no history of transient ischemic attack, stroke, or
carotid artery disease. Medical history and medications
were prospectively recorded. Patients were considered to
have hypercholesterolemia if they had a history of elevated
cholesterol concentrations or were taking a lipid-lowering
medication. Patients were considered to have coronary
artery disease if they had a history of coronary artery disease,
angina, or myocardial infarction or if they had undergone
coronary artery bypass grafting or coronary artery angio-
plasty. Patients were considered to have other cardiac dis-
ease if they had a history of or had undergone an interven-
tion for congestive heart failure, valvular heart disease, or
cardiac arrhythmia or had a pacemaker or defibrillator
implanted.
Once screened, each subject underwent modified du-
plex scanning by a registered vascular technician, electro-
cardiography, and blood pressure measurement. The pro-
tocol for our modified duplex scanning and its validation
study have been published.16 Stenosis of 50% or greater was
defined by peak systolic velocity greater than 125 cm/s.
The finding of carotid artery occlusion was considered to be
a positive result as far as screening was concerned. Experi-
enced registered vascular technicians in a laboratory accred-
ited by the Intersocietal Commission for the Accreditation
of Vascular Laboratories performed the modified carotid
duplex scanning.16
Screening tests were free to patients, and were available
on several days between June 2001 and September 2002.
The New York University School of Medicine Institutional
Review Board approved the study, and all patients signed
informed consent forms.
Statistical analysis. Data were maintained in a com-
puterized database, and were analyzed with SPSS statistical
software (SPSS Inc, Chicago, Ill). Statistical comparisons
were performed with the two-tailed Student t test for
comparison of continuous variables, and either 2 analysis
or the Fisher exact test for comparison of discrete variables.
Multivariate analysis was performed with binary logistic
regression. P  .05 was considered statistically significant.
Variables that reached significance of 0.2 or less at univar-
iate analysis were entered into the multivariate model.
RESULTS
Screening was performed in 610 patients. Unilateral or
bilateral CAS was detected in 66 patients (10.8%). The
finding of occult CAS was more prevalent than that of new
hypertension (2.6%) or new atrial fibrillation (0.5%).
Patient demographic data. Demographic data for
the 610 patients who underwent screening are presented in
Table I.
Overall screening results. Of 610 patients who un-
derwent screening, results were positive in 82 patients
(13.4%), indicating newly diagnosed atrial fibrillation, hy-
pertension, or CAS. The relationships between various
demographic factors and positive screening test results are
given in Table II. Patients with heart disease were signifi-
cantly more likely to have positive screening results than
were patients without heart disease (19.4% vs 11.1%; P 
.007).
CAS screening results. Of 610 patients who under-
went screening, 66 patients (10.8%) had newly diagnosed
unilateral or bilateral CAS. The relationship between vari-
ous demographic factors and the finding of occult CAS are
shwon in Table III. Patients with hypertension were signif-
Table I. Demographic data for patient population
Demographic factor n %
Current smoker 58 9.5
Hypertension 378 62
Heart disease 170 27.9
Coronary artery disease 106 17.4
Family history of stroke 318 52.1
Hypercholesterolemia 272 44.6
Male gender 223 36.6
White race 525 86.1
Age (y)
Mean 70.8
Range 60-91
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icantly more likely to have positive carotid screening results
than were those without hypertension (12.7% vs 7.8%; P
.05). Patients with heart disease were significantly more
likely to have occult CAS than were those without heart
disease (18.2% vs 8.0%; P  .001). Patients with both
hypertension and heart disease (n 104) were significantly
more likely to have occult CAS than were those without
either of these risk factors (22.1% vs 8.5%; P .001). There
was no relationship between systolic or diastolic blood
pressure measured at the screening and the finding of
occult CAS (Table III).
Of the 66 patients with newly diagnosed unilateral or
bilateral CAS, 57 patients (86.4%) underwent follow-up
formal carotid duplex scanning. One carotid occlusion was
identified; severity of the remainder of the lesions was in the
range of 50% to 79% with University of Washington crite-
ria.
Relationship between type of heart disease and CAS
among screened patients. Of 170 patients with known
heart disease, coronary artery disease was present in 105
patients (61.8%), atrial fibrillation in 30 patients (17.6%),
other arrhythmias or pacemaker insertion in 26 patients
(15.3%), and congestive heart failure or valvular heart dis-
ease in 9 patients (5.3%). Although a history of coronary
artery disease in and of itself was predictive of CAS at
univariate analysis (17.9% vs 9.3%; P  .01), there was no
particular relationship overall between type of heart disease
and presence of CAS (Fig 1). At multivariate analysis,
coronary artery disease was not a significant independent
predictor of CAS, whereas heart disease was.
Relationship between risk factors and presence of
bilateral carotid artery disease. Of the 610 patients
screened, 17 patients (2.8%) had bilateral CAS. An analysis
was performed to determine the relationship of various
demographic risk factors and presence of bilateral carotid
artery disease (Fig 2). Patients with occult bilateral CAS
had an increased incidence of atherosclerotic risk factors
compared with patients with unilateral occult CAS and
patients without CAS. For heart disease, 3 2 contingency
table analysis was statistically significant, at P  .001.
Table II. Relationship between patient variables and positive screening test results
Factor
Positive
(%) Factor
Positive
(%) P
Male gender 12.6 Female gender 14.0 .6
Current smoker 19.0 Nonsmoker 12.7 .2
Hypertension 13.5 No hypertension 13.4 1
Heart disease 19.4 No heart disease 11.1 .007
Family history of stroke 10.1 No family history of stroke 17.1 .01
Hypercholesterolemia 14.7 No hypercholesterolemia 12.4 .4
White race 13.9 Black race 9.8 .6
Coronary artery disease 17.9 No coronary artery disease 12.5 .18
Mean age of patients with positive
screening results (y)
71.8 Mean age of patients with negative screening results (y) 70.6 .16
Mean blood pressure in patients with
positive screening results (mm Hg)
Mean blood pressure in patients with
negative screening results (mm Hg)
Systolic 143 Systolic 140 .5
Diastolic 80 Diastolic 80 .5
Table III. Relationship between patient variables and occult carotid artery stenosis
Factor
Positive
screening
(%) Factor
Positive
screening
(%) P
Male gender 9.9 Female gender 11.4 .6
Current smoker 17.2 Nonsmoker 10.1 .1
Hypertension 12.7 No hypertension 7.8 .05
Heart disease 18.2 No heart disease 8.0 .001
Family history of stroke 7.2 No family history of stroke 14.7 .004
Hypercholesterolemia 13.2 No hypercholesterolemia 8.9 .08
White race 11.0 Black race 7.3 .5
Coronary artery disease 17.9 No coronary disease 9.3 .01
Hypertension and heart disease 22.1 No hypertension or heart disease 8.5 .0001
Mean age of patients with positive
screening results (y)
72 Mean age of patients with negative
screening results (y)
70.1 .16
Mean blood pressure in patients with
occult CAS (mm Hg)
Mean blood pressure in patients
without occult CAS (mm Hg)
Systolic 141 140 .9
Disastolic 77 80 .8
CAS, Carotid artery stenosis.
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Multivariate analysis. To determine the significant
independent predictors of occult CAS, multivariate analysis
with a binary logistic regression model was performed. All
variables that approached statistical significance at univari-
ate analysis with a P value  0.2 were included in the
multivariate analysis. Significant independent predictors of
CAS included heart disease, current cigarette smoking, and
hypertension (Table IV). Although a family history of
stroke appeared to have a negative association with occult
CAS at univariate analysis, this factor was not significant at
multivariate analysis.
Screening costs. Direct costs of the screening in-
cluded personnel (nurses, vascular technologists, electro-
cardiographic technicians), printing (pamphlets, posters,
stationary), advertising, postage, and supplies. Equipment
and space costs were not included. The number of patients
screened and the direct costs of screening per patient for
three representative screening sessions is shown in Fig 3. As
the program developed, efficiency improved such that
more patients could be screened in the same amount of
time. This and other factors resulted in a reduced direct cost
of screening per patient as the program progressed. Mean
direct screening cost per patient over these three represen-
tative sessions was $75.
DISCUSSION
To prevent stroke, some type of screening or assess-
ment is required to identify patients who may be at risk for
stroke. It is estimated that 20% to 75% of strokes in the
United States are caused by cervical carotid artery disease,
with the remainder caused by atrial fibrillation and hyper-
tension.14,32 These three immediate causes of stroke often
do not produce initial premonitory symptoms; in addition,
appropriate early management of these conditions can pre-
vent future strokes.14 However, there remains considerable
controversy as to which patients are appropriate for screen-
ing and how the evaluations should be performed. The
major unresolved issues include defining an appropriate
population for screening and achieving cost-effective
screening. It is clear that if a population with an increased
prevalence of these diseases could be defined, and the costs
of screening could be reduced, ultimately cost-effectiveness
would improve.
The epidemiology of carotid atherosclerosis has been
extensively studied. In a subset of the Framingham Study17
involving 1116 patients, multivariate logistic regression
revealed that age, cigarette smoking, systolic blood pres-
sure, and cholesterol levels were independently related to
carotid atherosclerosis. However, the prevalence of signif-
icant CAS in the general population was low, approximately
8%. In the Tromso Study18 an analysis of 6727 patients
who were screened for CAS reached similar conclusions as
in the Framingham Study, but additionally found that male
Table IV. Significant independent predictors of carotid
artery stenosis at multivariate analysis
Factor P
Odds
ratio
95% Confidence
interval
Lower Upper
Cardiac disease .001 2.5 1.4 4.4
Current smoking .023 2.5 1.1 5.7
Hypertension .048 1.9 1.0 3.4
Fig 3. Direct costs per patient (black squares) per screening ses-
sion. Gray bars indicate number of patients screened.
Fig 1. Relationship between types of heart disease and occult CAS
among screened patients (n  170). Gray bars, Number of pa-
tients; black diamonds, percent of patients with CAS. CAD, Cor-
onary artery disease; CAS, carotid artery stenosis.
Fig 2. Comparison of prevalence of demographic risk factors in
patients without CAS (black bars), with unilateral CAS (light gray
bars), and with bilateral CAS (dark gray bars). CAS, Carotid artery
stenosis; Hi chol, hypercholesterolemia; Htn, hypertension.
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gender was an independent predictor. In a study of risk
factors associated with internal carotid artery occlusion,
Bogousslavsky et al19 found that smoking, family history of
stroke, and obesity were more prevalent than in age-
matched and sex-matched patients without cerebrovascular
disease. Lernfelt et al20 found that bilateral carotid athero-
sclerosis was correlated with systolic blood pressure and
ischemic heart disease, and predicted the risk for stroke and
mortality in men. Finally, the SMART study21 found that
the prevalence of CAS increased as much as 50% in patients
with peripheral arterial disease. It is apparent from these
studies that traditional atherosclerotic risk factors are clearly
associated with development of carotid atherosclerotic dis-
ease.
Screening for carotid artery disease has been examined
widely as well. A variety of populations have been selected
for screening purposes. Cheng et al22 found that routine
carotid screening is worthwhile in elderly men with periph-
eral vascular disease. A number of other reports have de-
fined additional appropriate screening populations, includ-
ing all patients older than 60 years undergoing open heart
surgery,23,24 all patients older than 65 years referred to a
vascular surgeon,25 all male patients with symptomatic
lower extremity atherosclerosis,26 elderly patients with pe-
ripheral vascular disease with atherosclerotic risk factors,27
and patients with ankle-brachial index less than 0.7.28
However, recent extensive data from the SMART Study29
suggest that, although carotid screening is worthwhile in
patients with known peripheral arterial disease or abdomi-
nal aortic aneurysm, it cannot be endorsed for patients who
merely have risk factors for atherosclerosis alone. Finally,
one study30 suggested that investigating for CAS in sub-
jects without symptoms may actually be harmful; these
authors believe the risks of angiography and subsequent
CEA essentially outweigh the benefits of diagnosing
asymptomatic CAS.
The cost-effectiveness of screening remains an unavoid-
able issue. Holloway et al,9 in a systematic review of cost-
effectiveness research of stroke evaluation and treatment,
found that the reports that addressed the cost-effectiveness
of screening for asymptomatic CAS reached strikingly di-
vergent conclusions, from extremely cost-effective to ex-
ceedingly detrimental. Yin and Carpenter12 found that
screening for asymptomatic CAS was cost-effective when
the disease prevalence was 4.5% or more, specificity of the
test was 91% or more, stroke rate in medically treated
patients was 3.3% or more, relative risk reduction of surgery
was 37% or more, stroke rate associated with surgery was
160% or less than that of the North American Symptomatic
Carotid Endarterterectomy Trial31 or the Asymptomatic
Carotid Atherosclerosis Study,32 and cost of ultrasound
screening was $300 or less. Derdeyn et al8 also found that a
one-time screening program in an asymptomatic popula-
tion with a high prevalence of CAS may be cost-effective.
The cost-effectiveness of CEA itself has been examined,
and found favorable in most circumstances.7,10
Carotid duplex ultrasound scanning is arguably time-
intensive, and requires considerable technical expertise and
specialized equipment. When these examinations are per-
formed as a screening test for occult CAS, they are currently
not reimbursed by Medicare. Authors examining this issue
have reported that the Health Care Financing Administra-
tion has substantially undervalued the costs of performing
duplex scanning33 and that Medicare denial of noninvasive
vascular diagnostic tests can lead to uncompensated physi-
cian and hospital technical fees.34 Passman et al34 also
found that during one year in a hospital-based vascular
laboratory 408 carotid duplex scanning examinations were
performed. Of these 408 tests, 19.6% were denied by
Medicare; however, 72.5% of these same scans demon-
strated abnormal results.34 Clearly some sort of reevalua-
tion or reform is required. The performance of abbreviated
duplex scanning as a screening test, with more formal
scanning reserved for patients with 50% or greater stenosis,
may be a more cost-effective strategy.14-16
The current report differs from many of the cited
reports on carotid screening in several ways. Most of the
other “screening”-type studies reported in the literature
were performed in patients with known peripheral vascular
disease or who were already referred to a vascular surgeon.
The goal of this study was primarily to prospectively iden-
tify an unselected patient population that would benefit
from stroke screening. To make screening both efficient
and cost-effective, a population with a high prevalence of
disease must be defined. We deliberately did not choose
patients referred to our practices, because we believed this
would bias patients toward a higher prevalence of carotid
artery disease. The patients came from the community, and
were chosen on the basis of risk factors alone. We believe
this information is crucial to eventually justify Medicare
reimbursement of such screening. Certainly a prevalence of
20% in subsets of our screening population is a higher
prevalence of disease than would be expected with screen-
ing mammography or Papanicolaou testing. Finally, our
strategy was intended only as a stroke prevention screening
program, whereas the recent national screening program of
the American Vascular Association screened for all types of
peripheral arterial occlusive disease, including CAS, ab-
dominal aortic aneurysm, and lower extremity arterial oc-
clusive disease.
The most common treatable cause of stroke discovered
in this selected screening population was occult CAS. This,
then, is presumed to be the most crucial area in which there
is potential for aggressive intervention to prevent future
stroke. Hypertension and atrial fibrillation are more likely
to be noted in a routine visit to a primary care practitioner,
whereas CAS cannot be definitively diagnosed at physical
examination alone. Our abbreviated duplex scanning en-
abled diagnosis of stenosis of 50% or greater, and certainly
most of these patients are not immediate candidates for
carotid artery intervention. However, natural history stud-
ies have shown that in many patients with a moderate
degree of CAS the disease will progress to severe stenosis or
become symptomatic within a relatively short time.35,36
Certainly the diagnosis of occult CAS, even if moderate,
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should prompt more vigorous risk factor modification and
perhaps use of anti-platelet medications.
Second, a high-risk population has been clearly defined.
Patients with any history of medications or interventions
for cardiac disease were significantly more likely to have
both a positive screening test overall, as well as to have
occult CAS. Patients with both cardiac disease and hyper-
tension represent an extremely high-risk cohort of subjects
with regard to occult CAS. In a typical cardiology practice,
one can imagine that at least 75% of patients would fit this
category. Additional independent risk factors for occult
CAS at multivariate analysis included current cigarette
smoking and hypertension, factors that have been noted in
previous comparable epidemiologic studies. Similar to the
results in the current report, the Western New York Stroke
Screening Program37 found that significant variables asso-
ciated with CAS include age greater than 65 years, current
smoking, coronary artery disease, and hypercholesterol-
emia. Although family history of stroke appeared to be
negatively associated with CAS, we believe this may be an
inaccurate variable; family history of stroke was not a sig-
nificant independent predictor at multivariate analysis.
Screening a population with a high prevalence of dis-
ease will lead to both more effective and more efficient
screening processes. Finally, this screening program has
successfully decreased the time required to test for the three
most common causes of stroke; therefore it can be pre-
sumed that the cost should be decreased as well. Increased
efficiency on the part of our staff, nurses, and vascular
technologists with abbreviated scanning has further re-
duced the time and expenditure required in the most recent
screening sessions.
CONCLUSIONS
In a screening program for treatable causes of potential
stroke, CAS was the most commonly diagnosed entity.
More than one of every five patients within known hyper-
tension and heart disease had occult CAS. Known heart
disease of any type was a significant independent predictor
of occult CAS, as were current cigarette smoking and
hypertension. This information could help to further target
populations to screen for occult CAS and to justify reim-
bursement for screening carotid duplex scanning examina-
tions. If it is assumed that CEA and other stroke prevention
measures are ultimately both beneficial and cost-effective,
screening for treatable causes of potential stroke can also be
cost-effective.
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DISCUSSION
Dr Wesley S. Moore (Los Angeles, Calif). Dr Rockman, that
was an excellent presentation and a very carefully analyzed dataset.
I think it’s going to be extremely helpful to those of us who are
trying to justify carrying out carotid duplex scan screening of
patients who have appropriate risk factors.
This screening program is somewhat reminiscent of screening
for patients with abdominal aortic aneurysm. In those instances,
while the occurrence of small aneurysms, and perhaps small carotid
stenoses, was fairly common, the number of patients who actually
had lesions that were appropriate for surgery was few.
I wonder if you can share with us this morning the percentage
of patients who had lesions perhaps in the 60% to 79%, or perhaps
the 80% to 99% stenosis category, which would have demanded
surgical treatment early on, as opposed to those who have lesions
that will just simply be followed up.
Dr Caron B. Rockman. Thank you for those comments, Dr.
Moore.
I must tell you that unfortunately it’s quite difficult when you
screen patients to obtain ideal follow-up. We make recommenda-
tions to the patients and their primary care practitioners to get a
formal carotid duplex scan, but the patients did not always follow
up with that recommendation.
However, we did get formal duplex scans on nearly 90% of
these patients. We identified one patient with a carotid occlusion.
There were actually no patients in this series who had a severe
stenosis in the 80% to 99% range; we did not stratify in the
moderate range between 50% and 60%, and 60% and 79%.
That could be considered a criticism of our screening in that
we haven’t identified patients who need carotid intervention right
now. But I would counter that by saying that we’re not doing this
to simply identify surgical patients, but to increase overall patient
awareness and national awareness of stroke that there are ways to
prevent strokes from occurring.
Dr John J. Ricotta (Stony Brook, NY). You said there was no
relationship to age. That is not only counterintuitive, but flies in
the face of a lot of other data that suggest that carotid stenosis is
associated with age.
What was the age range of your screening population? Do you
think that you failed to find a correlation because of the age range
of the screening?
Dr Rockman. I think so. I think we really have selected out
our older patients to begin with, and that’s why we didn’t find a
relationship. Our age range was 60 to 90. In our analysis, we
examined age both as a continuous variable with t test analysis as
well as by dividing the patients into two sections based on 80 years
of age. There was still no statistically significant relationship.
Other studies have found a very significant relationship be-
tween age and the prevalence of carotid artery disease. However,
most of those screening studies have screened patients who are
much younger. I believe we probably selected our population to
begin with, and within this particular population there was no
relationship noted.
Dr Ricotta. Well, Nick Kouchoukos’s data actually show over
60, a very nice increase with age. You might want to look at age as
a continuous variable.
Dr John Blebea (Hershey, Pa). I think it is important in
reviewing these data to emphasize that when we, as surgeons, talk
about screening, we are assuming that risk factors exist in the
people who are being examined. We are not screening just anyone
walking in through the door. That is important because others do
not necessarily share that assumption when the term “screening” is
used.
As recently as last week at the American Institute of Ultra-
sound in Medicine annual meeting, the Committee on Standards
reviewed and approved a policy statement concluding that screen-
ing of asymptomatic patients for carotid disease is not justified.
However, it was recognized that people with identified risk factors
are justified in undergoing screening. Therefore studies such as
these are important in identifying and documenting that there are
population factors for carotid disease. When we talk about and
propose screening programs, therefore, we are not talking about
general population screening programs but screening of people
with identified risk factors.
I also have a question to ask you. I recognize the need to
measure the blood pressure in studies such as these, to document
the presence of hypertension. But do you, in fact, need to do that?
If such a screening program is to be instituted more broadly, is a
history alone of hypertension sufficient to define the person to be at
high risk for carotid arterial disease?
Dr Rockman. I think, in answer to your second question, a
history of hypertension alone probably is sufficient. I also think,
frankly, it’s difficult to make a definitive diagnosis of new hyper-
tension based on one blood pressure measurement. It’s true that if
we can eliminate the blood pressure measurement at the screening,
we may be able to further streamline the process.
I also agree completely with your first statement. I think also,
as surgeons, we have to take an overall interest in stroke prevention
and can’t just present to people that we’re just trying to identify
patients to operate on; we need to see this problem as a more global
issue.
Dr William R. Flinn (Baltimore, Md). Dr Rockman, we are
indebted to your group for stimulating this interest in screening for
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